Regulatory rejections and clinical trial failures are forcing biopharma companies to restructure in an effort to save costs.
Tag Archive for: Galera
August kicked off with two FDA approvals—for Merck’s Ebola vaccine in kids and Taiho’s combination therapy for metastatic colorectal cancer—and another rejection for Mesoblast’s aGVHD treatment.
